Any feedback?
Literature summary for 2.3.1.67 extracted from
- Anti-platelet-activating factor effects of highly active antiretroviral therapy (HAART): a new insight in the drug therapy of HIV infection? (2008), AIDS Res. Hum. Retroviruses, 24, 1079-1086.
Application
| Application | Comment | Organism |
|---|---|---|
| medicine | the results increases the understanding of the clinical implications of platelet-activating factor inhibition with regard to HIV infection | Homo sapiens |
Inhibitors
| Inhibitors | Comment | Organism | Structure |
|---|---|---|---|
| lopinavir-r | remaining activity in human mesangial cells: 76%. By contrast no effect on activity is observed in blood of naiive patients treated with the drug | Homo sapiens |  |
| tenofovir-DF | remaining activity in human mesangial cells: 32%. By contrast no effect on activity is observed in blood of naiive patients treated with the drug | Homo sapiens | |
Natural Substrates/ Products (Substrates)
| Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
|---|---|---|---|---|---|---|
| 1-O-hexadecyl-sn-glycero-3-phosphocholine + acetyl-CoA | Homo sapiens | lyso-PAF, lyso-platelet-activating factor | 1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine + CoA | PAF, platelet-activating factor | ? | |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Homo sapiens | - |
- |
- |
Source Tissue
| Source Tissue | Comment | Organism | Textmining |
|---|---|---|---|
| blood | - |
Homo sapiens | - |
| HMC cell | human mesangial cell line | Homo sapiens | - |
| mesangial cell | human mesangial cell line | Homo sapiens | - |
Specific Activity [micromol/min/mg]
| Specific Activity Minimum [µmol/min/mg] | Specific Activity Maximum [µmol/min/mg] | Comment | Organism |
|---|---|---|---|
| additional information | - |
specific activity of 32.4%, 1.7 ng/microl Tenofovir-DF in the cell incubation medium of HMC | Homo sapiens |
| additional information | - |
specific activity of 76.2%, 1.9 ng/microl Lopinavir-r in the cell incubation medium of HMC | Homo sapiens |
Substrates and Products (Substrate)
| Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
|---|---|---|---|---|---|---|
| 1-O-hexadecyl-sn-glycero-3-phosphocholine + acetyl-CoA | lyso-PAF, lyso-platelet-activating factor | Homo sapiens | 1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine + CoA | PAF, platelet-activating factor | ? | |
| lyso-platelt activating factor + acetyl-CoA | - |
Homo sapiens | ? | - |
? | |
Synonyms
| Synonyms | Comment | Organism |
|---|---|---|
| lyso-PAF-acetyltransferase | - |
Homo sapiens |
| Lyso-PAF-AT | - |
Homo sapiens |
Temperature Optimum [°C]
| Temperature Optimum [°C] | Temperature Optimum Maximum [°C] | Comment | Organism |
|---|---|---|---|
| 37 | - |
assay at | Homo sapiens |
| 37 | - |
activity assay | Homo sapiens |
pH Optimum
| pH Optimum Minimum | pH Optimum Maximum | Comment | Organism |
|---|---|---|---|
| 7.4 | - |
assay at | Homo sapiens |
| 7.4 | - |
activity assay | Homo sapiens |
Cofactor
| Cofactor | Comment | Organism | Structure |
|---|---|---|---|
| acetyl-CoA | - |
Homo sapiens | |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
